CDKN2A

Across TCGA pan-cancer cohorts, CDKN2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDKN2A data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDKN2A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDKN2A expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where CDKN2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.327	0.760	.035	8	view →
LUAD	DFS	Median	II,III,IV	0.861	0.225	.023	4	view →
LSCC	DFS	Tertile	II,III,IV	0.892	0.190	.024	2	view →
GBM	OS	Quartile	All	0.756	0.366	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDKN2A–PDAC (DFS)

Open the PDAC breakdown →